Last updated on July 2019

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin


Brief description of study

This randomized phase II/III trial studies how well radiation therapy works with durvalumab or cetuximab in treating patients with head and neck cancer that has spread to a local and/or regional area of the body who cannot take cisplatin. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as durvalumab or cetuximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not known if radiation therapy with durvalumab will work better than the usual therapy of radiation therapy with cetuximab in treating patients with head and neck cancer.

Detailed Study Description

PRIMARY OBJECTIVES:

I. To determine the safety of radiotherapy (RT) with concurrent and adjuvant anti-PD-L1 therapy (MEDI4736 [durvalumab]) is safe in patients with locoregionally advanced head and neck cancer (HNC) who have a contraindication to cisplatin. (Lead-in) II. To test the hypothesis that concurrent RT and anti-PD-L1 therapy improves progression free survival (PFS) compared to standard therapy (RT with concurrent cetuximab) in patients with locoregionally advanced HNC who have a contraindication to cisplatin. (Phase II) III. To test the hypothesis that concurrent RT and anti-PD-L1 therapy improves overall survival compared to standard therapy (RT with concurrent cetuximab) in patients with locoregionally advanced HNC who have a contraindication to cisplatin. (Phase III)

SECONDARY OBJECTIVES:

I. To compare toxicity using Common Terminology Criteria for Adverse Events (CTCAE) and Patient Reported Outcomes (PRO)-CTCAE between patients treated with RT + anti-PD-L1 therapy versus RT/cetuximab.

II. To test the effect of anti-PD-L1 therapy in the subpopulation of patients with tumors that overexpress PD-L1.

III. To compare overall survival, response (at 4-month fludeoxyglucose F-18 [FDG]-positron emission tomography [PET]-computed tomography [CT]), locoregional failure, distant metastasis, and competing mortality in the two arms by known risk factors, including p16 status and omega score.

IV. To test the hypothesis that MEDI4736 (durvalumab) therapy arm will have less decline in the physical function domain of European Organization for Research and Treatment of Cancer Core Questionnaire (EORTC QLQ-C30 version 3.0) based on the change in score from baseline to 12 months from end of RT, compared to the cetuximab-RT arm in patients with locoregionally advanced HNC who have a contraindication to cisplatin.

V. To test the hypothesis that MEDI4736 (durvalumab) therapy arm at 1 year (from end of RT) will have less decline in swallowing related quality of life (QOL) using the M. D. Anderson Dysphagia Inventory (MDADI) total composite score, based on the change in score from baseline to 12 months from end of RT, compared to the cetuximab-RT arm in patients who are medically unfit for cisplatin.

VI. To compare swallowing related performance and function short and long term using the Performance Status Scale for Head & Neck Cancer Patients (PSS-HN).

VII. To evaluate gastrostomy tube retention rates between arms.

EXPLORATORY OBJECTIVES:

I. To test the hypothesis that radiation combined with MEDI4736 (durvalumab) enhances the adaptive immune response using three types of immunophenotyping compared to radiation combined with cetuximab.

II. To compare overall QOL short term (end RT-8 months) and long term (12-24 months from end of RT) between arms using the EORTC QLQ-C30 version 3.0/HN35.

III. To evaluate swallowing related QOL short term (end RT-8 months) and long term (12-24 months from end of RT) using the EORTC Head and Neck (HN)35 swallowing domain and MDADI (subscales) between arms in patients with locoregionally advanced HNC who have a contraindication to cisplatin.

IV. To evaluate patient reported fatigue using the fatigue items in the EORTC QLQ and PRO-CTCAE.

V. To compare clinician and patient reported toxicity using CTCAE and PRO CTCAE.

VI. To explore health utilities between cetuximab and MEDI4736 (durvalumab) RT using the European Quality of Life 5 Dimensional-5 Level (EQ5D-5L).

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive cetuximab intravenously (IV) weekly over 60-120 minutes. Treatment repeats every week for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Beginning 5-7 days after first cetuximab dose, patients undergo intensity modulated radiation therapy (IMRT) 5 fractions per week for up to 7 weeks.

ARM II: Patients receive durvalumab IV over 60 minutes every 4 weeks. Treatment repeats every 4 weeks for up to 7 cycles in the absence of disease progression or unacceptable toxicity. Beginning week 2, patients undergo IMRT 5 fractions per week for up to 7 weeks.

After completion of study treatment, patients are followed up at 1 month, every 4 months for 1 year, every 6 months for 2 years, then annually thereafter.

Clinical Study Identifier: NCT03258554

Find a site near you

Start Over

Decatur Memorial Hospital

Decatur, IL United States
  Connect »

Spartanburg Medical Center

Spartanburg, SC United States
  Connect »

NRG Oncology

Philadelphia, PA United States
  Connect »

University Pointe

West Chester, OH United States
  Connect »

Community Cancer Center East

Indianapolis, IN United States
  Connect »

Penrose-Saint Francis Healthcare

Colorado Springs, CO United States
  Connect »

McKee Medical Center

Loveland, CO United States
  Connect »

Yale University

New Haven, CT United States
  Connect »

Moffitt Cancer Center

Tampa, FL United States
  Connect »

Queen's Medical Center

Honolulu, HI United States
  Connect »

Northwestern University

Chicago, IL United States
  Connect »

Crossroads Cancer Center

Effingham, IL United States
  Connect »

Carle Cancer Center

Urbana, IL United States
  Connect »

Community Cancer Center South

Indianapolis, IN United States
  Connect »

Community Cancer Center North

Indianapolis, IN United States
  Connect »

Henry Ford Hospital

Detroit, MI United States
  Connect »

Weisberg Cancer Treatment Center

Farmington Hills, MI United States
  Connect »

McLaren-Greater Lansing

Lansing, MI United States
  Connect »

McLaren Cancer Institute-Macomb

Mount Clemens, MI United States
  Connect »

McLaren-Port Huron

Port Huron, MI United States
  Connect »

Henry Ford West Bloomfield Hospital

West Bloomfield, MI United States
  Connect »

Saint Francis Medical Center

Cape Girardeau, MO United States
  Connect »

CHI Health Saint Francis

Grand Island, NE United States
  Connect »

Margaret R Pardee Memorial Hospital

Hendersonville, NC United States
  Connect »

Aultman Health Foundation

Canton, OH United States
  Connect »

Good Samaritan Hospital

Corvallis, OR United States
  Connect »

Kaiser Permanente Northwest

Portland, OR United States
  Connect »

Geisinger Medical Center

Danville, PA United States
  Connect »

University of Virginia Cancer Center

Charlottesville, VA United States
  Connect »

Regions Hospital

Saint Paul, MN United States
  Connect »

Saint Joseph Mercy Hospital

Ann Arbor, MI United States
  Connect »

ProHealth D N Greenwald Center

Mukwonago, WI United States
  Connect »

Miller-Dwan Hospital

Duluth, MN United States
  Connect »

Iowa Methodist Medical Center

Des Moines, IA United States
  Connect »

Abington Memorial Hospital

Abington, PA United States
  Connect »

Parkview Hospital Randallia

Fort Wayne, IN United States
  Connect »

Boston Medical Center

Boston, MA United States
  Connect »

Baptist MD Anderson Cancer Center

Jacksonville, FL United States
  Connect »

Memorial Medical Center

Springfield, IL United States
  Connect »

UCSF Medical Center-Mount Zion

San Francisco, CA United States
  Connect »

Poudre Valley Hospital

Fort Collins, CO United States
  Connect »

Mayo Clinic

Rochester, MN United States
  Connect »

Reading Hospital

West Reading, PA United States
  Connect »

Norris Cotton Cancer Center-North

Saint Johnsbury, VT United States
  Connect »

Community Memorial Hospital

Menomonee Falls, WI United States
  Connect »

UPMC-Shadyside Hospital

Pittsburgh, PA United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.